Back to Search
Start Over
Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
- Source :
- European Eating Disorders Review; May2016, Vol. 24 Issue 3, p223-231, 9p
- Publication Year :
- 2016
-
Abstract
- In a published 11-week, placebo-controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three-Factor Eating Questionnaire [TFEQ]; Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]; and the Barratt Impulsiveness Scale, version 11 [BIS-11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES ( p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y-BOCS-BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS-11 total score at 70 mg/d LDX ( p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p<0.05). These findings indicate that LDX decreased global binge eating severity and obsessive-compulsive and impulsive features of BED in addition to binge eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10724133
- Volume :
- 24
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- European Eating Disorders Review
- Publication Type :
- Academic Journal
- Accession number :
- 114245320
- Full Text :
- https://doi.org/10.1002/erv.2418